Results 221 to 230 of about 57,324 (252)
Some of the next articles are maybe not open access.
Exploiting Cytokines in Adoptive T-Cell Therapy of Cancer
Immunotherapy, 2015Adoptive immunotherapy with tumor-reactive autologous T cells, either expanded from tumor specimens or genetically engineered to express tumor-reactive T-cell receptors and chimeric antigen receptors, is holding promising results in clinical trials. Several critical issues have been identified and results underline the possibility to exploit cytokines ...
Elisabetta Petrozziello +2 more
openaire +2 more sources
Adoptive T cell therapy: points to consider
Current Opinion in Immunology, 2018Adoptive Cell Therapy (ACT) has enjoyed a revival in recent years with the approval of CAR T cells for the treatment of patients with B cell malignancies. Advancing the use of adoptively transferred T cells for the treatment of patients with solid tumor and other hematologic malignancies however, will require addressing numerous effector cell intrinsic
openaire +2 more sources
Critical care management of chimeric antigen receptor T-cell therapy recipients
Ca-A Cancer Journal for Clinicians, 2022Sandrine Valadè +2 more
exaly
Cryopreservation of T cells for adoptive T cell therapy
Cryobiology, 2015Victoria Sheard +4 more
openaire +1 more source
[Adoptive T-cell therapy of rhabdomyosarcoma].
Der Pathologe, 2011To improve survival of patients with advanced rhabdomyosarcomas (RMS), we aimed to adoptively transfer T-cells with redirected specificity for the fetal acetylcholine receptor (AChR), an RMS-specific cell surface antigen.A "second generation" chimeric antigen receptor (CAR) with a combined CD28-CD3ζ signaling domain was derived from our previously ...
K, Simon-Keller +10 more
openaire +1 more source
A review of cancer immunotherapy toxicity
Ca-A Cancer Journal for Clinicians, 2020Lucy Boyce Kennedy
exaly